VBI Vaccines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

VBI Vaccines Inc. (Nasdaq: VBIV) announced participation in analyst-led fireside chats at two investor conferences. The first is Guggenheim’s 4th Annual Immunology and Neurology Day on November 15, 2022, where CFO Christopher McNulty will present from 3:20-3:45 PM ET. The second is the Jefferies London Healthcare Conference on November 16, 2022, with President & CEO Jeff Baxter presenting from 8:00-8:30 AM GMT. Live webcasts will be available on VBI’s website, with replays archived post-event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following investor conferences:

Guggenheim’s 4^th Annual Immunology and Neurology Day

Date: Tuesday, November 15, 2022
Time: 3:20-3:45PM ET
Presenter: Christopher McNulty, CFO & Head of Business Development

Jefferies London Healthcare Conference

Date: Wednesday, November 16, 2022
Time: 8:00-8:30AM GMT
Presenter: Jeff Baxter, President & CEO

Live webcasts of the presentations will be available on the Investors page of VBI’s website at: https://www.vbivaccines.com/investors/events-and-presentations/. A replay of the webcast will be archived on the Company’s website following the presentation.

About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, visit www.vbivaccines.com.

Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic and the ongoing effects of the COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to successfully manufacture and commercialize PreHevbrio/PreHevbri; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio/PreHevbri; the ability to obtain appropriate or necessary regulatory approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 7, 2022, and filed with the Canadian security authorities at sedar.com on March 7, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005275/en/

VBI Contact

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: IR@vbivaccines.com

Source: VBI Vaccines Inc.

FAQ

What are the details of VBI Vaccines' participation in the Guggenheim Conference?

VBI Vaccines Inc. will participate in Guggenheim’s 4th Annual Immunology and Neurology Day on November 15, 2022, from 3:20-3:45 PM ET, presented by CFO Christopher McNulty.

When is VBI Vaccines presenting at the Jefferies London Healthcare Conference?

VBI Vaccines will present at the Jefferies London Healthcare Conference on November 16, 2022, from 8:00-8:30 AM GMT, led by President & CEO Jeff Baxter.

Where can I watch the VBI Vaccines presentations online?

Live webcasts of the VBI Vaccines presentations can be accessed on their Investors page, with recordings available after the events.

What is the business focus of VBI Vaccines Inc.?

VBI Vaccines Inc. focuses on developing vaccines using virus-like particle technology to prevent diseases such as hepatitis B and aggressive cancers.